Treatment completed for all patients in Parkinson’s trial – Scoop.co.nz (press release)

Posted: Published on May 1st, 2017

This post was added by Dr. Richardson

Living Cell Technologies Limited ACN: 104 028 042 ASX: LCT OTCQX: LVCLY

ASX ANNOUNCEMENT

Treatment completed for all patients in Parkinsons trial

1 May 2017 Sydney, Australia & Auckland, New Zealand Living Cell Technologies Limited has completed treatment of all six patients in the third and final group of patients in the Phase IIb clinical trial of NTCELL for Parkinsons disease, at Auckland City Hospital.

Four patients had 120 NTCELL microcapsules implanted into the putamen on each side of their brain, and two patients had sham surgery with no NTCELL implanted. To date there are no safety issues in any of the six patients.

The company is blind to the results until 26 weeks after the completion of group 3 of the trial. The results will then be analysed in accordance with the statistical plan and the conclusions announced. This is anticipated to occur in November 2017. Thereafter the patients who received the placebo will receive the optimal treatment.

The Phase IIb trial aims to confirm the most effective dose of NTCELL, define any placebo component of the response and further identify the initial target Parkinsons disease patient sub group. Providing the trial is successful, the company will apply for provisional consent in Q4 2017 with a view to treating paying patients in New Zealand in 2018.

The completion of treatment for the patients in group 3 brings us a step closer to our goals of obtaining provisional consent and launching NTCELL as the first disease modifying treatment for Parkinsons disease, says Dr Ken Taylor, CEO of Living Cell Technologies.

Ends

Scoop Media

Excerpt from:
Treatment completed for all patients in Parkinson's trial - Scoop.co.nz (press release)

Related Posts
This entry was posted in Parkinson's Treatment. Bookmark the permalink.

Comments are closed.